95 related articles for article (PubMed ID: 7341291)
1. Theoretical considerations and practical concerns regarding the use of continuous cell lines in the production of biologics.
Petricciani JC; Salk PL; Salk J; Noguchi PD
Dev Biol Stand; 1981; 50():15-25. PubMed ID: 7341291
[TBL] [Abstract][Full Text] [Related]
2. Tumorigenicity of continuous monkey cell lines in in vivo and in vitro systems.
Johnson JB; Noguchi PD; Browne WC; Petricciani JC
Dev Biol Stand; 1981; 50():27-35. PubMed ID: 6804291
[TBL] [Abstract][Full Text] [Related]
3. Loss of the tumorigenic phenotype with in vitro, but not in vivo, passaging of a novel series of human bronchial epithelial cell lines: possible role of an alpha 5/beta 1-integrin-fibronectin interaction.
Schiller JH; Bittner G
Cancer Res; 1995 Dec; 55(24):6215-21. PubMed ID: 8521416
[TBL] [Abstract][Full Text] [Related]
4. Administration of tumor cell chromatin to immunosuppressed and non-immunosuppressed non-human primates.
Wierenga DE; Cogan J; Petricciani JC
Biologicals; 1995 Sep; 23(3):221-4. PubMed ID: 8527121
[TBL] [Abstract][Full Text] [Related]
5. Continuous cell substrate considerations.
Lubiniecki AS
Bioprocess Technol; 1990; 10():495-513. PubMed ID: 1370028
[TBL] [Abstract][Full Text] [Related]
6. Use of the ATG-treated newborn rat for in vivo tumorigenicity testing of cell substrates.
van Steenis G; van Wezel AL
Dev Biol Stand; 1981; 50():37-46. PubMed ID: 6804292
[TBL] [Abstract][Full Text] [Related]
7. The tumorigenicity diversification in human embryonic kidney 293 cell line cultured in vitro.
Shen C; Gu M; Song C; Miao L; Hu L; Liang D; Zheng C
Biologicals; 2008 Jul; 36(4):263-8. PubMed ID: 18378163
[TBL] [Abstract][Full Text] [Related]
8. Risk assessment on the carcinogenic potential of hybridoma cell DNA: implications for residual contaminating cellular DNA in biological products.
Dortant PM; Claassen IJ; van Kreyl CF; van Steenis G; Wester PW
Biologicals; 1997 Dec; 25(4):381-90. PubMed ID: 9467034
[TBL] [Abstract][Full Text] [Related]
9. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.
Dhawan D; Ramos-Vara JA; Stewart JC; Zheng R; Knapp DW
Urol Oncol; 2009; 27(3):284-92. PubMed ID: 18562222
[TBL] [Abstract][Full Text] [Related]
10. Tumorigenicity, invasion and metastasis of the small cell lung cancer cell line NCI-H69 and two derivative lines MOG-H69V and MOG-H69VZ.
Khan MZ; McNicol AM; Freshney RI
Anticancer Res; 1996; 16(4A):1659-69. PubMed ID: 8712684
[TBL] [Abstract][Full Text] [Related]
11. Systematically experimental investigation on carcinogenesis or tumorigenicity of VERO cell lines of different karyotypes in nude mice in vivo used for viral vaccine manufacture.
Zhang DL; Ji L; Li LJ; Huang GS
Yi Chuan Xue Bao; 2004 Jul; 31(7):647-60. PubMed ID: 15473315
[TBL] [Abstract][Full Text] [Related]
12. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
[TBL] [Abstract][Full Text] [Related]
13. Tumourigenicity testing in immunosuppressed mice: advantages and disadvantages.
Stanbridge EJ; Perkins FT
Dev Biol Stand; 1976 Dec 13-15; 37():211-7. PubMed ID: 1031686
[TBL] [Abstract][Full Text] [Related]
14. Tumorigenicity testing of various cell substrates for production of biologicals.
Furesz J; Fanok A; Contreras G; Becker B
Dev Biol Stand; 1989; 70():233-43. PubMed ID: 2759351
[TBL] [Abstract][Full Text] [Related]
15. Safety issues relating to the use of mammalian cells as hosts.
Petricciani JC
Dev Biol Stand; 1985; 59():149-53. PubMed ID: 3891461
[TBL] [Abstract][Full Text] [Related]
16. Lipofection-mediated immortalization of human prostatic epithelial cells of normal and malignant origin using human papillomavirus type 18 DNA.
Weijerman PC; König JJ; Wong ST; Niesters HG; Peehl DM
Cancer Res; 1994 Nov; 54(21):5579-83. PubMed ID: 7923200
[TBL] [Abstract][Full Text] [Related]
17. Karyology and tumorigenicity testing requirements: past, present and future.
Petricciani JC; Horaud FN
Dev Biol Stand; 1998; 93():5-13. PubMed ID: 9737371
[TBL] [Abstract][Full Text] [Related]
18. Suppression of tumorigenicity, but not anchorage independence, of human cancer cells by new candidate tumor suppressor gene CapG.
Watari A; Takaki K; Higashiyama S; Li Y; Satomi Y; Takao T; Tanemura A; Yamaguchi Y; Katayama I; Shimakage M; Miyashiro I; Takami K; Kodama K; Yutsudo M
Oncogene; 2006 Nov; 25(56):7373-80. PubMed ID: 16767159
[TBL] [Abstract][Full Text] [Related]
19. Tumorigenicity assessments of Per.C6 cells and of an Ad5-vectored HIV-1 vaccine produced on this continuous cell line.
Ledwith BJ; Lanning CL; Gumprecht LA; Anderson CA; Coleman JB; Gatto NT; Balasubramanian G; Farris GM; Kemp RK; Harper LB; Barnum AB; Pacchione SJ; Mauer KL; Troilo PF; Brown ER; Wolf JJ; Lebronl JA; Lewis JA; Nichols WW
Dev Biol (Basel); 2006; 123():251-63; discussion 265-6. PubMed ID: 16566451
[TBL] [Abstract][Full Text] [Related]
20. Selection of cell lines with enhanced invasive phenotype from xenografts of the human prostate cancer cell line WPE1-NB26.
Rivette AS; Tokar EJ; Williams DE; Mackenzie CD; Ablin RJ; Webber MM
J Exp Ther Oncol; 2005; 5(2):111-23. PubMed ID: 16471037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
